FOLH1 and prostate carcinoma: Currently, the primary clinical indications for such radiopharmaceuticals include the diagnosis of prostate cancer and neuroendocrine tumors, using compounds targeting the prostate-specific membrane antigen (PSMA) [2] and somatostatin receptors (SSTR) [3], respectively.